Efficacy of delayed thromboprophylaxis with dabigatran: Pooled analysis

Thrombosis Research

Volumn 130, Issue 6, 2012, Pages 871-876

  Eriksson, Bengt I ^a   Dahl, Ola E ^b,f   Rosencher, Nadia ^c   Clemens, Andreas ^d   Hantel, Stefan ^d   Kurth, Andreas A ^e  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Centre of Medical Science   (Norway)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Bleeding; Dabigatran; Delayed dosing; Oral Direct Thrombin Inhibitor; Prophylaxis; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN ETEXILATE; ENOXAPARIN; PLACEBO;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; HIP ARTHROPLASTY; HUMAN; KIDNEY CLEARANCE; KNEE ARTHROPLASTY; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY (TOPIC); POST HOC ANALYSIS; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY DELAY; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; PROSPECTIVE STUDIES; PYRIDINES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84870244570     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.08.315     Document Type: Article

References (16)

1. W.H. Geerts, D. Bergqvist, G.F. Pineo, J.A. Heit, C.M. Samama, and M.R. Lassen Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 381S 453S
2. N. Ivanovic, M. Beinema, J.R. Brouwers, M. Naunton, and M.J. Postma Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban Expert Rev Pharmacoecon Outcomes Res 7 2007 49 58
3. CHMP Assessment Report for Pradaxa. European Medicine Agency. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000829/WC500041059.pdf. Accessed January 9, 2012.
4. Y. Falck-Ytter, C.W. Francis, N.A. Johanson, C. Curley, O.E. Dahl, and S. Schulman Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e278S e325S
5. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185
6. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956
7. Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. European Medicine Agency. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/WC500003301.pdf. Accessed January 9, 2012.
8. R.D. Hull, R.D. Yusen, and D. Bergqvist State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis Clin Appl Thromb Hemost 15 2009 377 388
9. O.E. Dahl, A.A. Kurth, N. Rosencher, H. Noack, A. Clemens, and B.I. Eriksson Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery Int Orthop 36 4 2012 741 748
10. Pradaxa Summary of Product Characteristics. Ingelheim, Germany: Boehringer Ingelheim. Available at www.medicines.org.uk/EMC/medicine/20760/SPC/ Pradaxa+110+mg+hard+capsules/ Accessed March 6, 2012.
11. R.D. Hull, G.F. Pineo, P.D. Stein, A.F. Mah, S.M. MacIsaac, and O.E. Dahl Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review Arch Intern Med 161 2001 1952 1960
12. G.E. Raskob, and J. Hirsh Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery Chest 124 2003 379S 385S
13. N. Strebel, M. Prins, G. Agnelli, and H.R. Buller Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 162 2002 1451 1456
14. O.E. Dahl Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen Clin Appl Thromb Hemost 15 Suppl. 1 2009 17S 24S
15. B.I. Eriksson, O.E. Dahl, H.R. Buller, R. Hettiarachchi, N. Rosencher, and M.L. Bravo A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial J Thromb Haemost 3 2005 103 111
16. B.I. Eriksson, O.E. Dahl, L. Ahnfelt, P. Kalebo, J. Stangier, and G. Nehmiz Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I J Thromb Haemost 2 2004 1573 1580